232 related articles for article (PubMed ID: 11431343)
1. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point.
Onda M; Kreitman RJ; Vasmatzis G; Lee B; Pastan I
J Immunol; 1999 Dec; 163(11):6072-7. PubMed ID: 10570296
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
4. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
Benhar I; Pastan I
J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
[TBL] [Abstract][Full Text] [Related]
5. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.
Benhar I; Padlan EA; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12051-5. PubMed ID: 7991583
[TBL] [Abstract][Full Text] [Related]
6. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
7. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice.
Benhar I; Reiter Y; Pai LH; Pastan I
Int J Cancer; 1995 Jul; 62(3):351-5. PubMed ID: 7628878
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
Reiter Y; Brinkmann U; Kreitman RJ; Jung SH; Lee B; Pastan I
Biochemistry; 1994 May; 33(18):5451-9. PubMed ID: 7910034
[TBL] [Abstract][Full Text] [Related]
9. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.
Reiter Y; Brinkmann U; Webber KO; Jung SH; Lee B; Pastan I
Protein Eng; 1994 May; 7(5):697-704. PubMed ID: 8073039
[TBL] [Abstract][Full Text] [Related]
10. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Brinkmann U; Reiter Y; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7538-42. PubMed ID: 8356052
[TBL] [Abstract][Full Text] [Related]
11. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
13. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
Bera TK; Onda M; Brinkmann U; Pastan I
J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland OS; Pastan I
J Immunother; 2001; 24(2):144-50. PubMed ID: 11265772
[TBL] [Abstract][Full Text] [Related]
16. Design of a modular immunotoxin connected by polyionic adapter peptides.
Kleinschmidt M; Rudolph R; Lilie H
J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
[TBL] [Abstract][Full Text] [Related]
17. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
18. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.
Kreitman RJ; Batra JK; Seetharam S; Chaudhary VK; FitzGerald DJ; Pastan I
Bioconjug Chem; 1993; 4(2):112-20. PubMed ID: 7873642
[TBL] [Abstract][Full Text] [Related]
19. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.
Beers R; Chowdhury P; Bigner D; Pastan I
Clin Cancer Res; 2000 Jul; 6(7):2835-43. PubMed ID: 10914732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]